Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells

Cancer Letters

Volumn 370, Issue 2, 2016, Pages 332-344

  Li, Zhen ^a   Jiang, Ke ^a   Zhu, Xiaofang ^b   Lin, Guibin ^a   Song, Fei ^a   Zhao, Yongfu ^a   Piao, Yongjun ^a   Liu, Jiwei ^a   Cheng, Wei ^a   Bi, Xiaolin ^a   Gong, Peng ^a   Song, Zhiqi ^a   Meng, Songshu ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b YANGZHOU UNIVERSITY   (China)

Author keywords

Autophagy; BRAF; Encorafenib (LGX818); Melanoma; Senescence

Indexed keywords

B RAF KINASE INHIBITOR; BETA GALACTOSIDASE; CASPASE 3; CELL CYCLE PROTEIN 6; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DACTOLISIB; DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1B; ENCORAFENIB; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE; RAPAMYCIN; RETINOBLASTOMA PROTEIN; S6 KINASE; UNCLASSIFIED DRUG; B RAF KINASE; BRAF PROTEIN, HUMAN; CARBAMIC ACID DERIVATIVE; CCND1 PROTEIN, HUMAN; CDKN1B PROTEIN, HUMAN; DYRK KINASE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MTOR PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MELANOMA CELL LINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENESCENCE; ANTAGONISTS AND INHIBITORS; CELL AGING; DRUG EFFECTS; GENETICS; MELANOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AUTOPHAGY; CARBAMATES; CELL AGING; CELL LINE, TUMOR; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; RETINOBLASTOMA PROTEIN; SULFONAMIDES; TOR SERINE-THREONINE KINASES;

EID: 84949513899     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.11.015     Document Type: Article

References (50)

1. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
2. Shepherd C., Puzanov I., Sosman J.A. B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr. Oncol. Rep 2010, 12:146-152.
3. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med 2011, 364:2507-2516.
4. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med 2010, 363:809-819.
5. Falchook G.S., Long G.V., Kurzrock R., Kim K.B., Arkenau T.H., Brown M.P., et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
6. Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
7. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med 2012, 366:707-714.
8. Haferkamp S., Borst A., Adam C., Becker T.M., Motschenbacher S., Windhovel S., et al. Vemurafenib induces senescence features in melanoma cells. J. Invest. Dermatol 2013, 133:1601-1609.
9. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol 2007, 8:729-740.
10. Young A.R., Narita M., Ferreira M., Kirschner K., Sadaie M., Darot J.F., et al. Autophagy mediates the mitotic senescence transition. Genes Dev 2009, 23:798-803.
11. Eskelinen E.L. New insights into the mechanisms of macroautophagy in mammalian cells. Int. Rev. Cell Mol. Biol 2008, 266:207-247.
12. Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol 2007, 8:741-752.
13. Gewirtz D.A. Autophagy, senescence and tumor dormancy in cancer therapy. Autophagy 2009, 5:1232-1234.
14. Goehe R.W., Di X., Sharma K., Bristol M.L., Henderson S.C., Valerie K., et al. The autophagy-senescence connection in chemotherapy: must tumor cells (self) eat before they sleep?. J. Pharmacol. Exp. Ther 2012, 343:763-778.
15. Qi M., Zhou H., Fan S., Li Z., Yao G., Tashiro S., et al. mTOR inactivation by ROS-JNK-p53 pathway plays an essential role in psedolaric acid B induced autophagy-dependent senescence in murine fibrosarcoma L929 cells. Eur. J. Pharmacol 2013, 715:76-88.
16. Grimaldi A.M., Cassidy P.B., Leachmann S., Ascierto P.A. Novel approaches in melanoma prevention and therapy. Cancer Treat. Res 2014, 159:443-455.
17. Urner-Bloch U., Urner M., Stieger P., Galliker N., Winterton N., Zubel A., et al. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann. Oncol 2014, 25:1437-1441.
18. Trinh V.A., You Y., Hwu W.J. Treatment of BRAF-mutated advanced cutaneous melanoma. Chin. Clin. Oncol 2014, 3:28.
19. Anforth R.M., Carlos G.R., Scolyer R.A., Chou S., Fernandez-Penas P. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma. Melanoma Res 2015, 25:91-94.
20. Ravnan M.C., Matalka M.S. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin. Ther 2012, 34:1474-1486.
21. Lemech C., Infante J., Arkenau H.T. Combination molecularly targeted drug therapy in metastatic melanoma: progress to date. Drugs 2013, 73:767-777.
22. Bian J., Wang K., Kong X., Liu H., Chen F., Hu M., et al. Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus. Arch. Virol 2011, 156:1335-1344.
23. Meng C., Zhou Z., Jiang K., Yu S., Jia L., Wu Y., et al. Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication. Arch. Virol 2012, 157:1011-1018.
24. Lee J.T., Li L., Brafford P.A., van den Eijnden M., Halloran M.B., Sproesser K., et al. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res 2010, 23:820-827.
25. Diehl J.A., Cheng M., Roussel M.F., Sherr C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998, 12:3499-3511.
26. Liu C., Li Y., Semenov M., Han C., Baeg G.H., Tan Y., et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002, 108:837-847.
27. Mizushima N. Autophagy. FEBS Lett 2010, 584:1279.
28. Ashford A.L., Oxley D., Kettle J., Hudson K., Guichard S., Cook S.J., et al. A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3beta to phosphorylate cyclin D1 at Thr(286), not Thr(288). Biochem. J. 2014, 457:43-56.
29. Paull T.T., Rogakou E.P., Yamazaki V., Kirchgessner C.U., Gellert M., Bonner W.M. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr. Biol 2000, 10:886-895.
30. Chandler H., Peters G. Stressing the cell cycle in senescence and aging. Curr. Opin. Cell Biol 2013, 25:765-771.
31. Beausejour C.M., Krtolica A., Galimi F., Narita M., Lowe S.W., Yaswen P., et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 2003, 22:4212-4222.
32. Ben-Porath I., Weinberg R.A. The signals and pathways activating cellular senescence. Int. J. Biochem. Cell Biol 2005, 37:961-976.
33. Rodier F., Campisi J. Four faces of cellular senescence. J. Cell Biol 2011, 192:547-556.
34. Ma X.H., Piao S.F., Dey S., McAfee Q., Karakousis G., Villanueva J., et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J. Clin. Invest 2014, 124:1406-1417.
35. Klionsky D.J., Abdalla F.C., Abeliovich H., Abraham R.T., Acevedo-Arozena A., Adeli K., et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012, 8:445-544.
36. McLeland C.B., Rodriguez J., Stern S.T. Autophagy monitoring assay: qualitative analysis of MAP LC3-I to II conversion by immunoblot. Methods Mol. Biol 2011, 697:199-206.
37. Mathew R., Karantza-Wadsworth V., White E. Role of autophagy in cancer. Nat. Rev. Cancer 2007, 7:961-967.
38. Liu T.J., Koul D., LaFortune T., Tiao N., Shen R.J., Maira S.M., et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol. Cancer Ther 2009, 8:2204-2210.
39. Sutherland C., Leighton I.A., Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J. 1993, 296(Pt 1):15-19.
40. Alao J.P., Stavropoulou A.V., Lam E.W., Coombes R.C. Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells. Mol. Cancer 2006, 5:40.
41. Yang K., Guo Y., Stacey W.C., Harwalkar J., Fretthold J., Hitomi M., et al. Glycogen synthase kinase 3 has a limited role in cell cycle regulation of cyclin D1 levels. BMC Cell Biol 2006, 7:33.
42. Boisvert-Adamo K., Aplin A.E. Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene 2008, 27:3301-3312.
43. Cartlidge R.A., Thomas G.R., Cagnol S., Jong K.A., Molton S.A., Finch A.J., et al. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res 2008, 21:534-544.
44. Paraiso K.H., Xiang Y., Rebecca V.W., Abel E.V., Chen Y.A., Munko A.C., et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011, 71:2750-2760.
45. Acosta J.C., Gil J. Senescence: a new weapon for cancer therapy. Trends Cell Biol 2012, 22:211-219.
46. Curry J.L., Falchook G.S., Hwu W.J., Torres-Cabala C.A., Duvic M., Tetzlaff M.T., et al. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. Am. J. Dermatopathol 2013, 35:125-128.
47. Gerland L.M., Peyrol S., Lallemand C., Branche R., Magaud J.P., Ffrench M. Association of increased autophagic inclusions labeled for beta-galactosidase with fibroblastic aging. Exp. Gerontol 2003, 38:887-895.
48. Patschan S., Goligorsky M.S. Autophagy: the missing link between non-enzymatically glycated proteins inducing apoptosis and premature senescence of endothelial cells?. Autophagy 2008, 4:521-523.
49. Gosselin K., Deruy E., Martien S., Vercamer C., Bouali F., Dujardin T., et al. Senescent keratinocytes die by autophagic programmed cell death. Am. J. Pathol 2009, 174:423-435.
50. Jinno-Oue A., Shimizu N., Hamada N., Wada S., Tanaka A., Shinagawa M., et al. Irradiation with carbon ion beams induces apoptosis, autophagy, and cellular senescence in a human glioma-derived cell line. Int. J. Radiat. Oncol. Biol. Phys 2010, 76:229-241.